MINT is a 12-week, exploratory, multi-center, prospective, randomized, double-blind, placebo-controlled trial of nintedanib + standard of care (SOC) immunosuppression (IS) vs placebo + SOC IS followed by an additional 12 weeks of open-label nintedanib plus SOC IS in all subjects. Subjects may be enrolled either through a local participating clinical trial site or remotely from anywhere in the U.S.A. via the coordinating site at the University of Pittsburgh. Steroid tapering and study drug dose modification are allowed.